Symptomatic vitreomacular adhesion treatment accepted for review by EMA

November 9, 2011

Ocriplasmin, a treatment for symptomatic vitreomacular adhesion, has been accepted for review by the European Medicines Agency (EMA).

Ocriplasmin, a treatment for symptomatic vitreomacular adhesion, has been accepted for review by the European Medicines Agency (EMA).

The 2.5 mg/mL solution for injection, developed by ThromboGenics (Leuven, Belgium), prevents retinal distortion and further decreases in vision in VMA patients including macular hole. If ocriplasmin is approved it will be the first pharmacological treatment for VMA including macular hole. The solution will be available in the EU and the US.

The CEO of ThromboGenics, Dr Patrik De Haes, said, “The global ThromboGenics team is proud to have achieved the successful acceptance for review of the European MAA for ocriplasmin, a major corporate milestone. Ocriplasmin is also expected to be filed with the FDA in the US by the end of the year. If approved, ocriplasmin will be the first pharmacological treatment for a condition that is currently only treated via surgery, and only after the patient’s vision has significantly deteriorated."

ThromboGenics completed two Phase II clinical trials for ocrimplasmin. The drug is currently in clinical trials for further vitreoretinal conditions. Dr De Haes said, “We are continuing to make excellent progress in building our commercial organization to educate and support the retina specialist community, with the aim of ensuring ocriplasmin achieves its full therapeutic potential and delivers maximum benefit to patients.”